(E)-3-(2-(aminomethyl)-3-fluoroallyl)phenol | 85278-80-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: (E)-3-(2-(aminomethyl)-3-fluoroallyl)phenol
• 英文别名: 2-(3'-hydroxy)benzyl-3-fluoroallylamine；3-[(E)-2-(aminomethyl)-3-fluoroprop-2-enyl]phenol
• CAS: 85278-80-4
• 化学式: C₁₀H₁₂FNO
• 分子量: 181.21
• InChiKey: WTBALKYUZKUGOM-RMKNXTFCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
  申请人：Wang Yanjun Eric

  公开号：US20070293548A1

  公开（公告）日：2007-12-20

  Compositions and methods of using compositions for treatment of inflammatory diseases and immune disorders are provided. Allylamino compounds are disclosed which are inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein 1 (VAP-1). The compounds have therapeutic utility in suppressing inflammation and inflammatory responses, and in treatment of several disorders, including multiple sclerosis and stroke.

  提供了用于治疗炎症性疾病和免疫紊乱的组合物及使用组合物的方法。公开了一种烯丙胺化合物，它们是半胱氨酸敏感胺氧化酶（SSAO）和/或血管粘附蛋白1（VAP-1）的抑制剂。这些化合物在抑制炎症和炎症反应方面具有治疗效用，并可用于治疗多发性硬化症和中风等多种疾病。
• INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT AND PREVENTION OF DISEASES
  申请人：WANG Eric Yanjun

  公开号：US20110269811A1

  公开（公告）日：2011-11-03

  Compositions and methods of using compositions for treatment of inflammatory diseases and immune disorders are provided. Allylamino compounds are disclosed which are inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein 1 (VAP-1). The compounds have therapeutic utility in suppressing inflammation and inflammatory responses, and in treatment of several disorders, including multiple sclerosis and stroke.

  提供了治疗炎症性疾病和免疫紊乱的组合物和使用组合物的方法。披露了抑制半胱氨酸敏感胺氧化酶（SSAO）和/或血管黏附蛋白1（VAP-1）的丙烯氨基化合物。这些化合物在抑制炎症和炎症反应以及治疗多种疾病，包括多发性硬化和中风方面具有治疗效用。
• Allyl amine MAO inhibitors
  申请人：MERRELL DOW FRANCE ET CIE

  公开号：EP0067105A2

  公开（公告）日：1982-12-15

  Compounds of the formula: wherein: R is 3,4-methylendioxyphenyl; phenyl; phenyl monosubstituted, disubstituted, or trisubstituted by (C1-C8)alkyl, (Cl-Ca)alkoxy, (C1-C6)alkylcarbonyloxy, hydroxy, chlorine, bromine, iodine, fluorine, trifluoromethyl, nitro, (C1-C6)alkylcarbonyl, benzoyl, or phenyl; 1- or 2-naphthyl; 1-, 2-, or 3-indenyl; 1-, 2-, or 9-fluorenyl; 2-pyridinyl; 1-, 2- or 3-piperidinyl; 2- or 3-pyrrolyl; 2- or 3-thienyl; 2- or 3-furanyl; 2- or 3-indolyl; 2- or 3-thianaphthenyl; or 2- or 3-benzofuranyl; R, is hydrogen, (C1-C8)alkyl, benzyl, or phenethyl; X and Y, independently, are hydrogen, fluorine, chlorine, or bromine; and A is a divalent radical of the formula: wherein R is hydrogen, methyl, or ethyl, and m and n, independently, are an integer from 0 to 4, provided that m + n cannot be greater than 4; -(CH2)p-D-(CH2)q-, wherein D is oxygen or sulfur, p is an integer from 2 to 4, and q is an integer from 0 to 2 provided that p + q cannot be greater than 4; or -(CH2),CH=CH(CH2)s-, wherein r is an integer from 1 to 3 and s is an integer from 0 to 2, provided that r + s cannot be greater than 3; or a non-toxic pharmaceutically acceptable acid addition salt thereof; provided that when each of X and Y in Formula I is hydrogen, R cannot be phenyl; are MAO inhibitors useful for treating depression. Processes and intermediates for preparing the compounds of Formula I or II are also described.

  式中的化合物： 式中 R 是 3,4-甲基己氧基苯基；苯基；由(C1-C8)烷基、(Cl-Ca)烷氧基、(C1-C6)烷基羰氧基、羟基、氯、溴、碘、氟、三氟甲基、硝基、(C1-C6)烷基羰基、苯甲酰基或苯基单取代、二取代或三取代的苯基；1-或 2-萘基；1-、2-或 3-茚基；1-、2-或 9-芴基；2-吡啶基；1-、2-或 3-哌啶基；2-或 3-吡咯基；2-或 3-噻吩基；2-或 3-呋喃基；2-或 3-吲哚基；2-或 3-噻吩基；或 2-或 3-苯并呋喃基； R，是氢、(C1-C8)烷基、苄基或苯乙基； X 和 Y、 分别是氢、氟、氯或溴；以及 A 是式中的二价基： 其中 R 是氢、甲基或乙基，m 和 n 分别是 0 至 4 的整数，但 m + n 不能大于 4； -(CH2)p-D-( )q-，其中 D 是氧或硫，p 是 2 至 4 的整数，q 是 0 至 2 的整数，但 p + q 不能大于 4；或 -( ),CH=CH( )s-，其中 r 是 1 至 3 的整数，s 是 0 至 2 的整数，但 r + s 不能大于 3； 或其无毒性的药学上可接受的酸加成盐；条件是当式 I 中的 X 和 Y 均为氢时，R 不能为苯基；这些化合物是用于治疗抑郁症的 MAO 抑制剂。还描述了制备式 I 或式 II 化合物的工艺和中间体。
• [EN] INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT AND PREVENTION OF DISEASES<br/>[FR] INHIBITEURS D'ADHÉRENCE MÉDIÉE PAR L'AMINE OXYDASE SENSIBLE AUX SEMI-CARBAZIDES (SSAO) ET LA VAP-1 UTILISÉS DANS LE TRAITEMENT ET LA PRÉVENTION DE MALADIES
  申请人：JOLLA PHARMA

  公开号：WO2007120528A2

  公开（公告）日：2007-10-25

  [EN] Compositions and methods of using compositions for treatment of inflammatory diseases and immune disorders are provided. Allylamino compounds are disclosed which are inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein 1 (VAP-I). The compounds have therapeutic utility in suppressing inflammation and inflammatory responses, and in treatment of several disorders, including multiple sclerosis and stroke.
  [FR] L'invention concerne des compositions et des méthodes d'utilisation des compositions dans le traitement de maladies inflammatoires et de troubles immuns. L'invention concerne également des composés allylamino qui constituent des inhibiteurs de l'amine oxydase sensible aux semi-carbazides (SSAO) et/ou de la protéine 1 d'adhérence vasculaire (VAP-I). Lesdits composés sont utilisés d'un point de vue thérapeutique dans la suppression de l'inflammation et des réponses inflammatoires, et dans le traitement de divers troubles, y compris la sclérose en plaques et l'accident vasculaire cérébral.